Literature DB >> 23964639

Radiofrequency ablation before intratumoral injection of (131)I-chTNT improves the tumor-to-normal tissue ratio in solid VX2 tumor.

Shu-Guang Zheng1, Hui-Xiong Xu, Ming-De Lu, Dian-Chao Yue, Xiao-Yan Xie, Guang-Jian Liu.   

Abstract

PURPOSE: This study was aimed to investigate whether the tumor necrosis induced by radiofrequency ablation (RFA) can improve the ratio of tumor-to-normal tissue (T/NT) after intratumoral injection of (131)I-chTNT. MATERIALS AND
METHOD: Eighteen New Zealand rabbits bearing VX2 tumor on the thigh were randomly divided into two treatment groups (control group: intratumoral injection of (131)I-chTNT alone; RFA group: RFA + intratumoral injection of (131)I-chTNT 3 days after RFA) and each group was further divided into three subgroups I, II, and III (1-2 cm, 2-3 cm, and 3-4 cm in maximum diameter, respectively), by the tumor size. SPECT was performed to evaluate the T/NT on days 1, 8, and 15 after (131)I-chTNT injection.
RESULTS: After treatment, all rabbits underwent the SPECT whole-body scan and the T/NT was analyzed. The results showed that T/NT in the RFA group (55.45±41.83) was significantly higher compared with the control group (7.23±5.61) (F=18.89, p=0.001). Meanwhile, a linear ascending trend was found for T/NT in the RFA group along with the follow-up time (r=0.47, p=0.01). The tumor size or the dose of (131)I-TNT injection had no significant effect on the variation of T/NT in both groups (p>0.05).
CONCLUSION: RFA before intratumoral injection of (131)I-chTNT can dramatically improve T/NT, demonstrating the potential application of this combination therapy.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23964639      PMCID: PMC3833304          DOI: 10.1089/cbr.2012.1418

Source DB:  PubMed          Journal:  Cancer Biother Radiopharm        ISSN: 1084-9785            Impact factor:   3.099


  31 in total

1.  Targeting radioimmunotherapy of hepatocellular carcinoma with iodine (131I) metuximab injection: clinical phase I/II trials.

Authors:  Zhi-Nan Chen; Li Mi; Jing Xu; Fei Song; Qing Zhang; Zheng Zhang; Jin-Liang Xing; Hui-Jie Bian; Jian-Li Jiang; Xian-Hui Wang; Peng Shang; Ai-Rong Qian; Si-He Zhang; Ling Li; Yu Li; Qiang Feng; Xiao-Ling Yu; Yuan Feng; Xiang-Min Yang; Rong Tian; Zhen-Biao Wu; Nan Leng; Ting-Shu Mo; An-Ren Kuang; Tian-Zhi Tan; Yun-Chun Li; De-Rong Liang; Wu-Sheng Lu; Jia Miao; Guo-Hui Xu; Zhi-Hui Zhang; Ke-Jun Nan; Jun Han; Qing-Guang Liu; Hong-Xin Zhang; Ping Zhu
Journal:  Int J Radiat Oncol Biol Phys       Date:  2006-06-01       Impact factor: 7.038

Review 2.  Radiofrequency ablation of solid tumors.

Authors:  A N Mirza; B D Fornage; N Sneige; H M Kuerer; L A Newman; F C Ames; S E Singletary
Journal:  Cancer J       Date:  2001 Mar-Apr       Impact factor: 3.360

Review 3.  Review of clinical radioimmunotherapy.

Authors:  Brad Pohlman; John Sweetenham; Roger M Macklis
Journal:  Expert Rev Anticancer Ther       Date:  2006-03       Impact factor: 4.512

4.  Pivotal study of iodine-131-labeled chimeric tumor necrosis treatment radioimmunotherapy in patients with advanced lung cancer.

Authors:  Shaoliang Chen; Like Yu; Changying Jiang; Yan Zhao; Da Sun; Shenyu Li; Guoqing Liao; Yangchun Chen; Qing Fu; Qun Tao; Dan Ye; Peisheng Hu; Leslie A Khawli; Clive R Taylor; Alan L Epstein; Dian Wen Ju
Journal:  J Clin Oncol       Date:  2005-03-01       Impact factor: 44.544

5.  Effects of 131I-labeled TNT-1 radioimmunotherapy on HT-29 human colon adenocarcinoma spheroids.

Authors:  F M Chen; C Z Liu; A L Epstein
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

Review 6.  Antibody-guided radiation therapy of cancer.

Authors:  Manuel J Koppe; Ernst J Postema; Frits Aarts; Wim J G Oyen; Robert P Bleichrodt; Otto C Boerman
Journal:  Cancer Metastasis Rev       Date:  2005-12       Impact factor: 9.264

Review 7.  Optimizing radioimmunoconjugate delivery in the treatment of solid tumor.

Authors:  Chen-Yu Huang; Mohammad H Pourgholami; Barry J Allen
Journal:  Cancer Treat Rev       Date:  2012-01-04       Impact factor: 12.111

8.  Biodistribution and localization of iodine-131-labeled metuximab in patients with hepatocellular carcinoma.

Authors:  Zheng Zhang; Huijie Bian; Qiang Feng; Li Mi; Tingshu Mo; Anren Kuang; Tianzh Tan; Yunchun Li; Wusheng Lu; Yang Zhang; Min Zhang; Rong Tian; Zhinan Chen; Ping Zhu
Journal:  Cancer Biol Ther       Date:  2006-03-20       Impact factor: 4.742

9.  131I-chTNT radioimmunotherapy of 43 patients with advanced lung cancer.

Authors:  Like Yu; Dian Wen Ju; Wenping Chen; Tian Li; Zhaoqiang Xu; Changying Jiang; Shaoliang Chen; Qun Tao; Dan Ye; Peisheng Hu; Leslie A Khawli; Clive R Taylor; Alan L Epstein
Journal:  Cancer Biother Radiopharm       Date:  2006-02       Impact factor: 3.099

10.  Tumor necrosis treatment of ME-180 human cervical carcinoma model with 131I-labeled TNT-1 monoclonal antibody.

Authors:  F M Chen; C R Taylor; A L Epstein
Journal:  Cancer Res       Date:  1989-08-15       Impact factor: 12.701

View more
  2 in total

1.  The safety and treatment response of combination therapy of radioimmunotherapy and radiofrequency ablation for solid tumor: a study in vivo.

Authors:  Shu-Guang Zheng; Hui-Xiong Xu; Le-Hang Guo; Lin-Na Liu; Feng Lu
Journal:  PLoS One       Date:  2014-05-02       Impact factor: 3.240

2.  Updated developments on molecular imaging and therapeutic strategies directed against necrosis.

Authors:  Dongjian Zhang; Meng Gao; Qiaomei Jin; Yicheng Ni; Jian Zhang
Journal:  Acta Pharm Sin B       Date:  2019-02-13       Impact factor: 11.413

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.